News headlines about Zogenix (NASDAQ:ZGNX) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Zogenix earned a news impact score of 0.24 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.34667777446 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Global Needle-Free Injection Device Market 2018 -Zogenix, Inovio, Glide Pharma, Akra Dermojet (marketingcorrect.com)
- Wired News – Shire Collaborates with NanoMedSyn to Treat Potential Lysosomal Storage Disorder (finance.yahoo.com)
- Zogenix, Inc. (ZGNX) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Zogenix (ZGNX) Given Buy Rating at Mizuho (americanbankingnews.com)
- Technical indicators to predict the future price movements of Zogenix, Inc. (ZGNX) – Wall Street Morning (wallstreetmorning.com)
ZGNX stock traded up $0.95 during midday trading on Thursday, hitting $40.05. The company’s stock had a trading volume of 425,829 shares, compared to its average volume of 567,458. Zogenix has a 1 year low of $10.05 and a 1 year high of $45.85. The stock has a market cap of $1,318.72, a P/E ratio of -8.63 and a beta of 1.57.
A number of equities analysts recently commented on the company. Mizuho reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Zogenix in a research note on Thursday, December 7th. BidaskClub raised Zogenix from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Zacks Investment Research raised Zogenix from a “sell” rating to a “hold” rating in a research note on Saturday, January 27th. Leerink Swann boosted their price objective on Zogenix from $50.00 to $54.00 and gave the company an “outperform” rating in a report on Friday, February 23rd. Finally, ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $53.20.
In related news, Director Roger Hawley sold 35,000 shares of the stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $44.71, for a total transaction of $1,564,850.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 5.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Zogenix (ZGNX) Earning Somewhat Favorable Press Coverage, Study Finds” was reported by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://baseballnewssource.com/2018/03/29/zogenix-zgnx-getting-somewhat-favorable-media-coverage-study-shows/1972926.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.